Extended Data Fig. 1: GSDME expression in human and mouse tumour cell lines.
From: Gasdermin E suppresses tumour growth by activating anti-tumour immunity
a, b, Gsdme messenger RNA (a) and protein (b) levels in the indicated mouse cancer cell lines, assessed by qPCR, relative to Gapdh (a), and by immunoblot (b). c, GSDME expression relative to GAPDH in normal tissue and tumours from breast invasive carcinoma (BRCA) and colon adenocarcinoma (COAD) patients from TCGA, compared with the qRT–PCR values for mouse cancer cell lines used here. P values comparing normal tissue and cancer tissues were calculated using unpaired two-tailed Student’s t-test. d, f, Expression of mGSDME in EMT6 (d) and CT26 (f) clones knocked out for Gsdme, or in control (Ctl) cells treated with nontargeting vector, assessed by immunoblot for GSDME. Actin serves as a loading control. e, g, Cell proliferation determined by CellTiter 96 in EMT6 (e) or CT26 (g) control and Gsdme knockout cells (n = 6 samples per group). h, Expression of hGSDME in SH-SY5Y clones knocked out for GSDME or in control cells treated with nontargeting vector, assessed by immunoblot for GSDME. i, j, Expression of mGSDME in GSDME-overexpressing (OE) and empty-vector-transduced B16 (i) or 4T1E (j) cells, assessed by immunoblot. k, Expression of hGSDME in GSDME-overexpressing and empty-vector-transduced HeLa cells, assessed by immunoblot. Differences among multiple groups in e, g were analysed by one-way ANOVA, using the Holm–Sidak method for multiple comparisons. P values in e, g compare knockout and control cells. ***P < 0.0001. Data are mean ± s.d. of three technical (a) or six biological (e, g) replicates. Data are representative of at least two independent experiments.
